Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

Cancer

Volumn 120, Issue 2, 2014, Pages 222-228

  Ahmadi, Tahamtan ^a   Chong, Elise A ^a   Gordon, Amanda ^a   Aqui, Nicole A ^a   Nasta, Sunita D ^a   Svoboda, Jakub ^a   Mato, Anthony R ^b   Schuster, Stephen J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

follicular lymphoma; immunomodulation; immunomodulatory therapy; lenalidomide; low grade; lymphoma; non Hodgkin lymphoma; rituximab

Indexed keywords

AMINOTRANSFERASE; DEXAMETHASONE; LENALIDOMIDE; RITUXIMAB;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DEFECATION DISORDER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; HYPERURICEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOMODULATION; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR FLARE;

EID: 84891868901     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28405     Document Type: Article

References (24)

1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 1417-1423.
2. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009; 27: 1607-1614.
3. Abdollahi S, Chong EA, Olin RL, et al. The impact of rituximab resistance on overall survival rate in low-grade follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 3783.
4. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). National Cancer Institute. Bethesda, MD: National Cancer Institute; 2012 (based on the November 2011 SEER data submission, posted to the SEER web site April 2012). Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed June 6, 2012.
5. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008; 140: 36-45.
6. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009; 114: 4713-4720.
7. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26: 4952-4957.
8. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011; 22: 1622-1627.
9. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27: 5404-5409.
10. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009; 145: 344-349.
11. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS,. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005; 11: 5984-5992.
12. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009; 84: 553-559.
13. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008; 14: 4650-4657.
14. Qian Z, Zhang L, Cai Z, et al. Lenalidomide synergies with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011; 35: 380-386.
15. Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1244.
17. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000; 18: 3135-3143.
18. Carver JR, Nasta S, Chong EA, et al. Myocarditis during lenalidomide therapy. Ann Pharmacother. 2010; 44: 1840-1843.
19. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012; 13: 716-723.
20. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia. 2013; 27: 1902-1909.
21. Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011; 11: 462-466.
22. DeRook I, Odonnell RT, Noble B, Quirch C, Tuscano J,. R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 3060.
23. Dutia M, Deroock I, Reed-Pease C, Tuscano J,. Lenalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed/refractory indolent non-Hodgkin's lymphoma [abstract]. Ann Oncol. 2011; 22 (suppl 4). Abstract iv186.
24. Fowler NH, Neelapu SS, Hagemeister FB, et al. Lenalidomide and rituximab for untreated follicular lymphoma: final results of a phase II study [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120. Abstract 901.